Avance Clinical’s Post

Did you miss Avance Clinical's live Psychedelics In Focus webinar on Monday? The webinar featured a fascinating conversation between Senior Director of Scientific and Regulatory Services, Jorgen Mould and Senior Vice President Scientific and Regulatory Affairs Kevin Leach, Ph.D, DABT. Delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Simply register via the Xtalks website 👇 https://lnkd.in/eywUiP3i #AvanceClinical #CRO #psychedelicscience #psychedelicresearch #clinicalresearch #newmedicines #depression #anxiety #webinar

Want to learn more about psychedelics such as LSD? You’ve come to the right place. Our free and extensive library contains over 300 articles written by health professionals and the psychedelic community. Psychedelic Support resources are growing every month. It can be overwhelming to find what you need. That’s why we’ve created a roundup and summary of the top 10 articles we have written about LSD. This includes: 1. LSD vs. Psilocybin 2. Comparing MDMA and LSD 3. Can LSD Improve Your Learning Potential? 4. LSD vs. Ayahuasca Experience: Which Psychedelic Therapy Is a Good Fit for You? 5. Can Psychedelics Cause Psychosis? 6. Can Psychedelics Help With Color Blindness? 7. What is Microdosing, and How Does it Work? 8. Can Microdosing Relieve Anxiety Symptoms? 9. The Diagnosis: Our Toxic Society 10. How To Join a Psychedelic Clinical Trial Find all of them with summaries here: https://lnkd.in/dYjwQTWb

Psychedelic therapy, utilizing substances like psilocybin and LSD, is gaining traction as a treatment for mental health conditions such as depression and PTSD. Despite promising results, the mainstream legalization and acceptance of psychedelic therapy still face regulatory hurdles and varying expert opinions on optimal administration methods and settings. The approach at institutions like the Geneva University Hospital involves coupling psychedelics with psychotherapy to maximize therapeutic benefits and guide patients through profound experiences. #PsychedelicTherapy #MentalHealthTreatment #RegulatoryHurdles #PsychotherapyIntegration #SwissHealthcare Read more here: https://lnkd.in/ejYNduG6 BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

🌟 What if denying access to psychedelics is akin to denying access to the COVID vaccine? In the latest article by The Evening Standard, Alexandra Jones delves deep into the groundbreaking insights of Professor David Nutt, a renowned neuropsychopharmacologist. He reveals why the time to legalize psychedelics is now, shedding light on their potential to revolutionize mental healthcare. His work illuminates not just the scientific community but also champions the cause for those of us engaged in therapeutic and ceremonial practices, by challenging societal norms, reducing stigma, and advocating for the acceptance and understanding of these transformative substances. 🧠 Professor Nutt's journey—from being sacked for advocating the truth about psychedelic drugs to becoming a beacon of hope for those seeking alternative mental health treatments—is nothing short of inspirational. Get to know his compelling perspective on how substances like psilocybin, LSD, DMT, and MDMA could offer a lifeline for individuals grappling with depression, PTSD, and addiction. 📖 Dive into the entire article and uncover Professor Nutt's insights on the challenges researchers face, the political landscape surrounding drug policy reform, and the ethical dilemmas of psychedelic therapy. 👉🏻 Read more: https://lnkd.in/ecYmk2uf 💬 Don't miss out on the discussion! Share your thoughts in the comments below. Do you believe in the transformative potential of psychedelic therapy? Let's ignite a dialogue and explore the future of mental health together. #MentalHealth #MattZemon #MentalHealthTalk #PsychedelicRevolution #MentalHealthAwareness @Professor David Nutt

🌟 Exciting News! 🌟 Join us for SWEET Institute's upcoming seminar on "Strategies to Improve Patient Medication Adherence." Are you looking for innovative ways to help your patients stay on track with their medications? Curious about the latest research and practical techniques? This seminar is designed for you! 🗓 Date: Sunday, August 11th 🕒 Time: 3-4p Let’s dive into: - Proven strategies to enhance medication adherence. - Practical tips for healthcare providers. - Real-world case studies and success stories. What challenges have you faced with patient medication adherence? What strategies have worked for you? Share your thoughts and let's learn together! #Healthcare #MedicationAdherence #PatientCare #SWEETInstitute #MedicalSeminar

Fasting interventions may reduce depressive symptoms, but how? In a new preprint, we show that higher plasma levels of acyl ghrelin are associated with an elevated mood in patients with depression and healthy participants. Our in-depth analyses show that the association of ghrelin with mood generalizes across items, is state-like, and attenuated in patients taking SSRIs. Work led by Rauda Fahed & Corinna Schulz #mentalhealth #mood #gut #psychology https://lnkd.in/eK7ckiKJ

Ketamine, developed as an anesthetic in 1962, has been widely misunderstood due to its journey from medical use to recreational associations. Known as a "horse tranquilizer" and "Special K" in rave culture, media sensationalism fueled misconceptions about its purpose. However, ketamine's therapeutic potential for depression and PTSD has emerged, with studies showing its effectiveness. Its unique properties, including pain relief and sedation, make it valuable in medical settings. Despite its initial associations, ketamine's role in mental health treatment is increasingly recognized, thanks to its ability to stimulate brain-derived neurotrophic factor (BDNF), promoting neurogenesis and synaptogenesis. To learn more about Ketamine treatments options at Luvita, book a discovery call : https://lnkd.in/gQgkt_ND #Ketamine #Therapy #Breakthrough #Education #PsychedelicCare #KetamineIVTherapy #MentalHealth #PsychedelicResearch #NovelTreatments

🧠✨ Exciting news! I've just published Part 2 of our deep dive into psychedelic therapies on Firing and Wiring. In this latest installment, we explore the complexities and controversies surrounding these groundbreaking treatments. While Part 1 introduced us to the transformative potential of psychedelics in psychiatric care, Part 2 tackles the harder questions: What are the ethical concerns and cultural controversies affecting the adoption of these therapies? How do recent setbacks, like the FDA advisory panel's decision against MDMA for PTSD, impact future research and acceptance? This series isn't just an exploration—it's a conversation. We need to critically assess both the potential and the pitfalls of integrating psychedelics into mainstream mental health treatment. Read the full article to get a balanced view of where these innovative therapies stand today and where they might go tomorrow. 🔗 https://lnkd.in/giYS_576 #PsychedelicTherapy #MentalHealth #Innovation #MDMA #PsychedelicResearch #Healthcare

I am delighted to inform you that I have collaborated as an author in a publication titled "A Survey on Respiratory and Neurological Symptoms in Alzheimer’s, Schizophrenia, Bipolar, and Migraine Patients Following COVID-19 Infection" published in the esteemed journal of Brieflands. This extensive study explores the multifaceted interactions between COVID-19, neurological complications, and mental health disorders (e.g., migraines, BD, and schizophrenia) to better understand their collective impact on individuals’ health and well-being.. Link: https://lnkd.in/d6_HwgiB #covid #isi #scientificresearch #nueroscience

We are devastated by the FDA’s plainly incorrect decision to reject the approval of MDMA-assisted therapy. There is an urgent need and clear demand from the Veteran community for new PTSD treatments, and MDMA-AT has demonstrated safety and profound efficacy in clinical trials based on protocols negotiated and agreed upon with the FDA as part of a Special Protocol Assessment. It is hard to see how the FDA’s decision can be justified when it has plenty of tools to ensure a slow, cautious roll-out of this novel treatment, which could have at least been conditionally approved with required safety data collection and post-marketing studies, as well as a more restrictive risk mitigation strategy. Instead, Veterans will continue to be forced to leave the country or to seek underground providers for MDMA-AT or other psychedelic therapies, which is a tragic and unconscionable outcome. While we remain confident MDMA-AT will eventually be approved, there is no doubt that this decision will lead to more unnecessary suffering and lives lost. However, Reason for Hope and the Veteran Mental Health Leadership Coalition, whose members and partner organizations have tirelessly advocated to make their voices heard, will continue doing whatever it takes to help get this across the finish line. Read more at the link in the comments. #mdmatherapy